What’s next for CAR-T cell therapy at Penn – Philadelphia Business Journal
|
What's next for CAR–T cell therapy at Penn
Philadelphia Business Journal Last week, Novartis received its second approval for Kymriah, a CAR–T cell therapy developed by researchers at Penn Medicine and Children's Hospital of Philadelphia. The therapy, which involves bioengineering a patient's own cells to boost their … |
